Raleigh drugmaker shifts focus after trial setback


After discontinuing a late-stage clinical trial for one of its drug candidates, a Raleigh company is advancing another asset in its pipeline and has secured debt financing to help.

Previous Pinnacle Financial Partners details growth pattern in Memphis within changing banking market
Next Fulton-based VC Conversion Capital closes $122M fund focused on fintech